Comparison 3. Long‐term treatment ‐ oral versus placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mean FEV1 at end of course (L)	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
1.1 >6 months and up to 12 months	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
2 Mean FVC at end of course (L)	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
2.1 >6 months and up to 12 months	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
3 Mortality	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
4 Weight (kg)	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
4.1 > 6 months and up to 12 months	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
5 Adverse events	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
5.1 Gastro‐intestinal	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
6 Participants needing additional IV courses	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
7 Isolation of antibiotic‐resistant strains ‐ P. aeruginosa	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
8 Isolation of antibiotic‐resistant strains ‐ S. aureus	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected